FRB antibodies
The invention provides anti-FRB antibodies or antigen binding fragments thereof that bind an FRB polypeptide.
1 . An anti-FKBP Rapamycin binding (FRB) antibody or antigen binding fragment thereof that binds an FRB polypeptide, wherein the antibody or antigen binding fragment thereof comprises a light chain variable region comprising the light chain CDRs (CDRL1-CDRL3) set forth in any one of SEQ ID NOs: 1-3, 11-13, 21-23, 31-33, and 41-43 and a heavy chain variable region comprising the heavy chain CDRs (CDRH1-CDRH3) set forth in any one of SEQ ID NOs: 4-6, 14-16, 24-26, 34-36, and 44-46.
2 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a light chain variable region comprising the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 1-3 and the heavy chain variable region comprising the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 4-6.
3 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a light chain variable region comprising the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 11-13 and the heavy chain variable region comprising the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 14-16.
4 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a light chain variable region comprising the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 21-23 and the heavy chain variable region comprising the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 24-26.
5 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a light chain variable region comprising the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 31-33 and the heavy chain variable region comprising the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 34-36.
6 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a light chain variable region comprising the light chain CDRs (CDRL1-CDRL3) set forth in SEQ ID NOs: 41-43 and the heavy chain variable region comprising the heavy chain CDRs (CDRH1-CDRH3) set forth in SEQ ID NOs: 44-46.
7 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a variable light chain sequence as set forth in any one of SEQ ID NOs: 7, 9, 17, 19, 27, 29, 37, 39, 47, and 49 and a variable heavy chain sequence as set forth in any one of SEQ ID NOs: 8, 10, 18, 20, 28, 30, 38, 40, 48, and 50.
8 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a variable light chain sequence as set forth in SEQ ID NO: 7 or SEQ ID NO: 9 and a variable heavy chain sequence as set forth in SEQ ID NO: 8 or SEQ ID NO: 10.
9 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a variable light chain sequence as set forth in SEQ ID NO: 17 or SEQ ID NO: 18 and a variable heavy chain sequence as set forth in SEQ ID NO: 19 or SEQ ID NO: 20.
10 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a variable light chain sequence as set forth in SEQ ID NO: 27 or SEQ ID NO: 28 and a variable heavy chain sequence as set forth in SEQ ID NO: 29 or SEQ ID NO: 30.
11 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a variable light chain sequence as set forth in SEQ ID NO: 37 or SEQ ID NO: 38 and a variable heavy chain sequence as set forth in SEQ ID NO: 39 or SEQ ID NO: 40.
12 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment thereof comprises a variable light chain sequence as set forth in SEQ ID NO: 47 or SEQ ID NO: 48 and a variable heavy chain sequence as set forth in SEQ ID NO: 49 or SEQ ID NO: 50.
13 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein (i) the antibody or antigen binding fragment comprises a variable heavy chain sequence, a polypeptide linker, and a variable light chain sequence or (ii) the antibody or antigen binding fragment comprises a variable light chain sequence, a polypeptide linker, and a variable heavy chain sequence.
14 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment.
15 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment is a single chain variable fragment (scFv).
16 . The anti-FRB antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or antigen binding fragment binds an FRB polypeptide sequence set forth in SEQ ID NO: 51.
17 . A conjugate, comprising the anti-FRB antibody or antigen binding fragment thereof of claim 1 and a detectable label.
18 . A polynucleotide encoding the anti-FRB antibody or antigen binding fragment thereof of claim 1 .
19 . A composition comprising the anti-FRB antibody or antigen binding fragment of claim 1 .
20 . A hybridoma comprising (i) the anti-FRB antibody or antigen binding fragment thereof of claim 1 , or (ii) one or more polynucleotides encoding the anti-FRB antibody or antigen binding fragment thereof of claim 1 .